Neurogene
NASDAQ: NGNE1 known investors
Neurogene develops gene therapies for rare neurological diseases, particularly Rett syndrome, using proprietary transgene regulation technology. The company serves patients and families affected by devastating neurological disorders.
Investors · 1
Competitors · 4
by search overlap
Biogen Idec35 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Regeneron NASDAQ: REGN www.regeneron.com29 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
NervGen Pharma22 shared keywordsNervGen is a clinical-stage biotech company developing therapies for neurological conditions, with a focus on spinal cord injury and neurorepair. It maintains a drug pipeline and operates as a publicly traded company.
Origene21 shared keywordsOriGene supplies research reagents including primary antibodies for flow cytometry, transfection kits (EZ-LNP and ProteanFect), RNAi gene silencing tools, and control solutions for life science laboratories. Its products serve researchers in molecular and cell biology.
Companies competing with Neurogene for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Neurogene do?
- Neurogene develops gene therapies for rare neurological diseases, particularly Rett syndrome, using proprietary transgene regulation technology. The company serves patients and families affected by devastating neurological disorders.
- Who are Neurogene's investors?
- Neurogene's investors include EcoR1 Capital.